AstraZeneca PLC stock (US6549022043): Full-year 2025 revenue surges 18% to $47.6B

AstraZeneca PLC released its full-year 2025 financial results on February 26, 2026, posting total revenue of $47.6 billion, a robust 18% increase at constant exchange rates from the prior year. Oncology sales led the growth, rising 25% to $19.0 billion, driven by blockbusters like Enhertu and Imfinzi, according to ad-hoc-news.de as of 02/26/2026. The company's ADR on Nasdaq climbed 1.47% to $184.54 on May 12, 2026, per StockInvest.us as of 05/12/2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

AstraZeneca PLC: core business model

AstraZeneca PLC develops and commercializes prescription medicines in three core therapy areas: Oncology, Cardiovascular, Renal & Metabolism (CVRM), and Respiratory & Immunology (R&I). Headquartered in Cambridge, UK, the company operates globally with a focus on innovation in high-growth segments like rare diseases and oncology.

The biopharmaceutical giant generates approximately 37% of its revenue from the US market, offering US investors direct exposure to global healthcare trends through its Nasdaq-listed ADR under ticker AZN. This listing facilitates easy trading for American portfolios seeking diversified pharma plays.

Main revenue and product drivers for AstraZeneca PLC

Oncology accounted for 40% of 2025 revenue at $19.0 billion, up 25% year-over-year, propelled by Enhertu and Imfinzi, as reported in the full-year 2025 results published February 26, 2026, per AstraZeneca IR as of 02/26/2026. CVRM and R&I segments also contributed significantly to the overall 18% growth.

Key products like Tagrisso in oncology and Farxiga in CVRM remain top revenue generators. The US represents a critical market, with strong demand for these therapies amid rising chronic disease prevalence.

Industry trends and competitive position

The global biopharma sector faces pricing pressures but benefits from oncology breakthroughs and aging populations. AstraZeneca PLC holds a strong position with its diversified portfolio, competing effectively against peers like Pfizer and Roche through targeted therapies.

Recent full-year results underscore resilience, with US market exposure enhancing appeal for investors tracking healthcare innovation.

Why AstraZeneca PLC matters for US investors

AstraZeneca PLC's Nasdaq ADR provides US investors seamless access to a global leader, with 37% US revenue tying performance to American healthcare spending. The stock's 2.1% dividend yield, based on 2025 payout equivalent to $3.00 per ADR, supports income strategies.

Trading at $184.54 USD on May 12, 2026 on Nasdaq, according to StockInvest.us as of 05/12/2026, it reflects stability in volatile markets.

Conclusion

AstraZeneca PLC's full-year 2025 results highlight sustained growth in oncology and core markets, with US revenue exposure bolstering relevance for American investors. The Nasdaq ADR's recent gains and dividend payout reflect operational strength amid biopharma dynamics. Ongoing innovation positions the company for continued focus in high-value therapy areas.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.